Cited by 1,394Antiplatelet Therapy and Cardiovascular DiseasesInflammatory mediators and NSAID effectsPlatelet Disorders and Treatments

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin

Open access

Catella-Lawson, Francesca, Reilly, Muredach P., Kapoor, Shiv C., Cucchiara, Andrew J., DeMarco, Susan, Tournier, Barbara, Vyas, Sachin N., FitzGerald, Garret A.·2001·New England Journal of Medicine

DOI 10.1056/nejmoa003199

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs. We therefore investigated potential interactions between aspirin and commonly prescribed arthritis therapies METHODS: We administered the following combinations of drugs for six days: aspirin (81 mg every morning) two hours before ibuprofen (400 mg every morning) and the same medications in the reverse order; aspirin two hours before acetaminophen (1000 mg every morning) and the same medications in the reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every morning) and the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 mg three times a day); and enteric-coated aspirin two hours before delayed-release diclofenac (75 mg twice daily) RESULTS: Serum thromboxane B(2) levels (an index of cyclooxygenase-1 activity in platelets) and platelet aggregation were maximally inhibited 24 hours after the administration of aspirin on day 6 in the subjects who took aspirin before a single daily dose of any other drug, as well as in those who took rofecoxib or acetaminophen before taking aspirin. In contrast, inhibition of serum thromboxane B(2) formation and platelet aggregation by aspirin was blocked when a single daily dose of ibuprofen was given before aspirin, as well as when multiple daily doses of ibuprofen were given. The concomitant administration of rofecoxib, acetaminophen, or diclofenac did not affect the pharmacodynamics of aspirin CONCLUSIONS: The concomitant administration of ibuprofen but not rofecoxib, acetaminophen, or diclofenac antagonizes the irreversible platelet inhibition induced by aspirin. Treatment with ibuprofen in patients with increased cardiovascular risk may limit the cardioprotective effects of aspirin.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa003199

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Bombardier, C., Laine, L., Reicin, A. S., Shapiro, D., Burgos‐Vargas, R., Davis, B. R., Day, R. O., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,014
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,267
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,572
Self-citation
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S. C., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,304
Self-citation
The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
Picot, D., Loll, P. J., & Garavito, R. M. (1994) · Nature · doi:10.1038/367243a0 · Cited by 1,270
Platelet-Active Drugs
Patrono, C., Coller, B. S., Dalen, J. E., Gerald, G. A. F., Fuster, V., Gent, M., Hirsh, J., & Roth, G. J. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.39s · Cited by 961
Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy Subjects
Patrignani, P., Filabozzi, P., & Patrono, C. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110576 · Cited by 931
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11475-1 · Cited by 829
Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
Luong, C., Miller, A. B., Barnett, J. W., Chow, J., Ramesha, C. S., & Browner, M. F. (1996) · Nature Structural Biology · doi:10.1038/nsb1196-927 · Cited by 620
Effects of Specific Inhibition of Cyclooxygenase-2 on Sodium Balance, Hemodynamics, and Vasoactive Eicosanoids
Catella-Lawson, F., McAdam, B. F., Morrison, B. W., Kapoor, S. C., Kujubu, D. A., Antes, L. M., Lasseter, K. C., Quan, H., Gertz, B. J., & FitzGerald, G. A. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38195-9 · Cited by 596
Self-citation
Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment
Funk, C. D., Funk, L. B., Kennedy, M. E., Pong, A. S., & FitzGerald, G. A. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.9.1907252 · Cited by 568
Self-citation
Dose-Related Kinetics of Aspirin
Pedersen, A. K., & FitzGerald, G. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411083111902 · Cited by 559
Self-citation
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases.
Patrignani, P., Panara, M. R., Greco, A., Fusco, O., Natoli, C., Iacobelli, S., Cipollone, F., Ganci, A., Créminon, C., & Maclouf, J. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24061-7 · Cited by 517
Epidemiology of NSAID induced gastrointestinal complications.
Singh, G., & Triadafilopoulos, G. (1999) · PubMed · Cited by 493
The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase
Loll, P. J., Picot, D., & Garavito, R. M. (1995) · Nature Structural Biology · doi:10.1038/nsb0895-637 · Cited by 490
Clinical pharmacology of platelet cyclooxygenase inhibition.
Patrono, C., Ciabattoni, G., Patrignani, P., Pugliese, F. R., Filabozzi, P., Catella, F., Davı̀, G., & Forni, L. (1985) · Circulation · doi:10.1161/01.cir.72.6.1177 · Cited by 454
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs
Reilly, I., & FitzGerald, G. (1987) · Blood · doi:10.1182/blood.v69.1.180.bloodjournal691180 · Cited by 416
Self-citation
Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonists
FitzGerald, G. A. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90379-y · Cited by 356
Self-citation
Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers
Hecken, A. V., Schwartz, J. I., Depré, M., Lepeleire, I. D., Dallob, A. L., Tanaka, W. K., Wynants, K., Buntinx, A., Arnout, J., Wong, P. H., et al. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001005 · Cited by 355
Relative Risk of Upper Gastrointestinal Complications among Users of Acetaminophen and Nonsteroidal Anti-Inflammatory Drugs
Rodríguez, L. A. G., & Hernández–Dı́az, S. (2001) · Epidemiology · doi:10.1097/00001648-200109000-00018 · Cited by 305
Estimated rate of prostacyclin secretion into the circulation of normal man.
FitzGerald, G. A., Brash, A. R., Falardeau, P., & Oates, J. A. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110373 · Cited by 269
Self-citation
Differential Effects of Aspirin and Non-Aspirin Nonsteroidal Antiinflammatory Drugs in the Primary Prevention of Myocardial Infarction in Postmenopausal Women
Rodriguez, L. A. G., Varas‐Lorenzo, C., & Patrono, C. (2000) · Epidemiology · doi:10.1097/00001648-200007000-00004 · Cited by 177
Synthesis and Use of Iodinated Nonsteroidal Antiinflammatory Drug Analogs as Crystallographic Probes of the Prostaglandin H2 Synthase Cyclooxygenase Active Site,
Loll, P. J., Picot, D., Ekabo, O. A., & Garavito, R. M. (1996) · Biochemistry · doi:10.1021/bi952776w · Cited by 164
Monitoring the entry of new platelets into the circulation after ingestion of aspirin
Minno, G. D., Silver, M., & Murphy, S. (1983) · Blood · doi:10.1182/blood.v61.6.1081.1081 · Cited by 141
Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding
Kaufman, D. W., Kelly, J. P., Sheehan, J. E., László, A., Wiholm, B., Alfredsson, L. S., Koff, R. S., & Shapiro, S. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.55 · Cited by 118
COX-2 is not involved in thromboxane biosynthesis by activated human platelets.
Patrignani, P., Sciulli, M. G., Manarini, S., Santini, G., Cerletti, C., & Evangelista, V. (1999) · PubMed · Cited by 115
Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol)
Grèen, K., Drvota, V., & Vesterqvist, O. (1989) · Prostaglandins · doi:10.1016/0090-6980(89)90001-4 · Cited by 112
Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction
Brochier, M. L. (1993) · European Heart Journal · doi:10.1093/eurheartj/14.7.951 · Cited by 97
Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin.
Rao, G. H. R., Johnson, G. G., Reddy, K. R., & White, J. G. (1983) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.3.4.383 · Cited by 97
The Interaction of Arginine 106 of Human Prostaglandin G/H Synthase-2 with Inhibitors Is Not a Universal Component of Inhibition Mediated by Nonsteroidal Anti-inflammatory Drugs
Greig, G. M., Francis, D. A., Falgueyret, J., Ouellet, M., Percival, M. D., Roy, P. J., Bayly, C. I., Mancini, J. A., & O’Neill, G. P. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.5.829 · Cited by 86
Remnants of suicidal cells fostering systemic autoaggression: Apoptosis in the origin and maintenance of autoimmunity
Rovere, P. Q., Sabbadini, M. G., Fazzini, F., Bondanza, A., Zimmermann, V. S., Rugarli, C., & Manfredi, A. A. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200008)43:8 · Cited by 85
Self-citation
Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions
Vesterqvist, O., & Gréen, K. (1984) · Prostaglandins · doi:10.1016/0090-6980(84)90098-4 · Cited by 71
Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity
Livio, M., Maschio, A. D., Cerletti, C., & de Gaetano, G. (1982) · Prostaglandins · doi:10.1016/0090-6980(82)90123-x · Cited by 71
A New Cyclooxygenase‐2 Inhibitor, Rofecoxib (VIOXX®), Did Not Alter the Antiplatelet Effects of Low‐Dose Aspirin in Healthy Volunteers
Greenberg, H. E., Gottesdiener, K. M., Huntington, M. F., Wong, P., Larson, P., Wildonger, L., Gillen, L. P., Dorval, E. P., & Waldman, S. A. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001224 · Cited by 70
Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study.
Fornaro, G., Rossi, P., Mantica, P., Caccia, M. E., Aralda, D., Lavezzari, M., Pamparana, F., & Milanesi, G. (1993) · Circulation · doi:10.1161/01.cir.87.1.162 · Cited by 63
Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing
Pedersen, A. K., & FitzGerald, G. A. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.8 · Cited by 53
Self-citation
Physiologic variables affecting thromboxane B2 production in human whole blood
Alessandrini, P., Avogaro, P., Bon, G. B., Patrignani, P., & Patrono, C. (1985) · Thrombosis Research · doi:10.1016/0049-3848(85)90027-1 · Cited by 46
Inhibitor-Induced Changes in the Intrinsic Fluorescence of Human Cyclooxygenase-2
Houtzager, V. M., Ouellet, M., Falgueyret, J., Passmore, L. A., Bayly, C. I., & Percival, M. D. (1996) · Biochemistry · doi:10.1021/bi960053m · Cited by 36
Antiplatelet Effects of MK‐852, a Platelet Fibrinogen Receptor Antagonist, in Healthy Volunteers
Greenberg, H. E., Wissel, P. S., Barrett, J., Barchowsky, A., Gould, R. J., Farrell, D., Panebianco, D. L., Hand, E. L., Gillen, L. P., Goldberg, M. R., et al. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022009116 · Cited by 27
Prostaglandins and the mode of action of antipyretic analgesic drugs
Brune, K. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90228-0 · Cited by 23
Prospective evaluation of the utilization of aspirin and non-steroidal anti-inflammatory drugs in acute medical admissions.
Pathmakanthan, S., Dg, O., Sheehan, K. M., & Murray, F. E. (1998) · PubMed · Cited by 9
The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis
Gravellese (2000) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200002)43:2 · Cited by 2
Untitled work
Santiago (2001) · doi:10.1002/1529-0131(200107)44:7
Untitled work
Atsumi (2000) · doi:10.1002/1529-0131(200009)43:9

Research works printed but not linked: 7

Singh G, 1999, J Rheumatol, 26, 18
Patrignani P, 1999, J Physiol Pharmacol, 50, 661
Pathmakanthan S, 1998, Ir Med J, 91, 58
Patrignani P, 1994, J Pharmacol Exp Ther, 271, 1705
Sciulli MG, Patrignani P, Seta F, et al. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells in vitro. In: Proceedings of the 11th International Conference on Advances in Prostaglandin and Leukotriene Research: Basic Science and New Clinical Applications, Florence, Italy, June 4–8, 2000:38. abstract.
Reilly IAG, 1987, Blood, 69, 180, 10.1182/blood.V69.1.180.180 · DOI
Catella-Lawson F, 1999, J Pharmacol Exp Ther, 289, 735

Sorted by citations

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
McCrindle, B. W., Rowley, A. H., Newburger, J. W., Burns, J. C., Bolger, A. F., Gewitz, M. H., Baker, A., Jackson, M. A., Takahashi, M., Shah, P. B., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000484 · Cited by 3,740
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease
Newburger, J. W., Takahashi, M., Gerber, M. A., Gewitz, M. H., Tani, L. Y., Burns, J. C., Shulman, S. T., Bolger, A. F., Ferrieri, P., Baltimore, R. S., et al. (2004) · Circulation · doi:10.1161/01.cir.0000145143.19711.78 · Cited by 1,928
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes
Bassand, J., Hamm, C. W., Ardissino, D., Boersma, E. H., Budaj, A., Fernández‐Avilés, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., Wallentin, L. C., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm161 · Cited by 1,860
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials
† (2013) · The Lancet · doi:10.1016/s0140-6736(13)60900-9 · Cited by 1,857

See all 1,394

Authors: Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A.
Affiliations: University of Pennsylvania (US)
ORCID: Reilly, Muredach P.
Kapoor, Shiv C.
Cucchiara, Andrew J.
Tournier, Barbara
FitzGerald, Garret A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-12-20
Volume: 345
Issue: 25
Pages: 1809-1817
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa003199
OpenAlex: W2011327495
Cited by: 1,394
References: 44
Citations by year: 2026: 19 · 2025: 15 · 2024: 18 · 2023: 18 · 2022: 33 · 2021: 43 · 2020: 33 · 2019: 40 · 2018: 40 · 2017: 46 · 2016: 41 · 2015: 56 · 2014: 46 · 2013: 69 · 2012: 79
FWCI: 50.64
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Heart, Lung, and Blood Institute (HL 5400, HL62250, P01HL062250)
National Center for Research Resources (M01-RR-00040, M01RR000040)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords: aspirin, ibuprofen, cyclooxygenase inhibitors, rofecoxib, diclofenac, paracetamol, drug interactions, platelet aggregation, thromboxane B2, antiplatelet activity, nonsteroidal anti-inflammatory drugs, arthritis treatment, cardiovascular risk, cardioprotection
MeSH terms: Acetaminophen, Adult, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Diclofenac, Drug Interactions, Drug Therapy, Combination, Humans, Ibuprofen, Isoenzymes, Lactones, Membrane Proteins, Middle Aged, Platelet Aggregation, Platelet Aggregation Inhibitors, Prostaglandin-Endoperoxide Synthases, Sulfones, Thromboxane B2, Dinoprostone, Cyclooxygenase Inhibitors, Cross-Over Studies, Analgesics, Non-Narcotic, Cyclooxygenase 1, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks